This dual agonism represents a novel pharmacological approach, targeting two complementary incretin pathways simultaneously rather than one
FIGURE 2 The random-effects relative treatment estimates versus metformin are shown in Figure 2B, followed by exploratory SUCRA and rank-probability summaries in Figures 2C,D and posterior density/ROPE summaries in Figure 2E
In this role, pharmacists serve as advocates, educators, and partners in caretransforming weight management from a daunting challenge into a supported, achievable journey
See Why 65,000+ People are Trying GobyMeds Real Results from Real People
The medication addresses the physiological mechanisms that drive hunger and weight rebound, making it especially valuable for individuals who lose weight initially but struggle with long-term maintenance